ArticleFrontiers in medicine2026
Relationships between serum angiogenesis markers and sarcopenia: a cross-sectional study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the associations between serum angiogenesis markers (VEGF, ANGPT1, and ANGPT2) and sarcopenia in older adults. Methods: This cross-sectional study included 471 older individuals admitted to Nanyang Central Hospital from May 2019 to May 2024. Sarcopenia was diagnosed using the Asian Working Group for Sarcopenia (AWGS) criteria, based on hand grip strength (HGS) and appendicular skeletal muscle mass (ASM). Serum levels of VEGF, ANGPT1, and ANGPT2 were measured, and statistical analyses included ROC curve analyses and logistic regression models to assess the relationships between angiogenesis markers and sarcopenia traits. Results: A total of 68 participants (14.44%) were diagnosed with sarcopenia. Significant decreases in VEGF and ANGPT1 levels were observed in the sarcopenia group compared to the normal cohort. Linear regression models showed that VEGF was positively correlated with HGS and ASM, while ANGPT1 was positively correlated with ASM. ROC curves indicated modest discriminatory ability for sarcopenia for both VEGF and ANGPT1. Logistic regression analysis revealed that low VEGF levels were associated with a higher risk of low HGS, low ASM, and sarcopenia, while low ANGPT1 levels were associated with increased risk of low ASM and sarcopenia (OR = 3.645, Conclusions: VEGF and ANGPT1 are significantly associated with sarcopenia and may provide incremental value to standard clinical assessments. Further longitudinal studies are needed to elucidate the underlying mechanisms linking angiogenesis markers to sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.